rofecoxib has been researched along with Myocardial Ischemia in 2 studies
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bogaty, P | 1 |
| Brophy, JM | 1 |
| Noel, M | 1 |
| Boyer, L | 1 |
| Simard, S | 1 |
| Bertrand, F | 1 |
| Dagenais, GR | 1 |
| Rotondo, S | 1 |
| Dell'Elba, G | 1 |
| Manarini, S | 1 |
| Cerletti, C | 1 |
| Evangelista, V | 1 |
1 trial available for rofecoxib and Myocardial Ischemia
| Article | Year |
|---|---|
Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Biomarkers; Brachial Artery; C-Rea | 2004 |
1 other study available for rofecoxib and Myocardial Ischemia
| Article | Year |
|---|---|
The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.
Topics: Acetates; Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Disease Models, Animal; Elect | 2006 |